.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical consequence of 11 months, clients with metastatic stomach lumps who got biomarker-matched treatments based upon circulating growth DNA profiling showed a better clinical perk than those acquiring unmatched treatment.